Skip to content
Open access

554. Kynurenic acid and promotion of activity-dependent synapse elimination in schizophrenia

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i239 - i240 · 0 citations

TL;DR

These findings link KYNA to excessive, activity-dependent synaptic elimination in human cellular models of schizophrenia and show that its dynamics are sensitive to immune signaling.

Abstract

Abstract Background Schizophrenia is associated with alterations in synaptic connectivity and brain signaling, which are thought to contribute to the disorder’s core cognitive and clinical features. A growing body of evidence implicates dysregulation of tryptophan metabolism along the kynurenine pathway in schizophrenia. Within this pathway, kynurenic acid (KYNA), a neuroactive metabolite modulating glutamatergic and cholinergic neurotransmission, is consistently found at elevated levels in the central nervous system of affected individuals. However, how KYNA release is regulated in human brain models, and how altered KYNA dynamics relate to synaptic abnormalities, requires further investigation. Aims & Objectives To investigate KYNA regulation in human cellular models of schizophrenia and to explore its possible contribution to synaptic dysfunction. Method Three independent experimental approaches were used to examine the role of KYNA in schizophrenia. First, patient-derived neuronal and microglial models were used to assess the impact of KYNA on activity-dependent synaptic uptake. Second, dorsal brain organoids derived from individuals with schizophrenia and matched controls were analyzed for spontaneous release of kynurenine pathway metabolites, including KYNA, and for expression of pathway-related genes using bulk RNA sequencing. Third, dorsal brain organoids were exposed to pro-inflammatory cytokines (IFN-γ and IL-1β) to examine the effect of immune signaling on KYNA production, and kynurenine aminotransferases (KAT) inhibition was applied to reduce KYNA release. Results (i) In neuronal and microglial models, elevated KYNA promoted activity-dependent microglial uptake of synaptic structures. (ii) Patient-derived brain organoids exhibited stable, spontaneous release of kynurenine pathway metabolites, with schizophrenia-derived organoids showing differential expression of pathway-related genes. (iii) In brain organoids, pro-inflammatory cytokines (IFN-γ and IL-1β) increased KYNA release, which was attenuated by pharmacological inhibition of KATs. Discussion & Conclusions These findings link KYNA to excessive, activity-dependent synaptic elimination in human cellular models of schizophrenia and show that its dynamics are sensitive to immune signaling. This platform enables mechanistic studies of KYNA, including manipulation of its release, and suggests that KAT inhibition may help preserve synapses.

Read PDF

Similar papers

Open access Sep 2026

434. The effect of kynurenic acid (KYNA) release on glutamatergic transmission in the hippocampus - a model of schizophrenia

Abstract Background Schizophrenia is a psychiatric disorder that has debilitating symptomatic manifestations, including psychotic episodes, depression-like symptoms, as well as cognitive dysfunction, all three of which contribute to the heavy disease burden for the individual. Multiple hypotheses have been developed in...

K. Jardemark, G. Engberg, K. Lindelöf et al. · 0 citations
Review Open access Sep 2026

Epilepsy as a Disorder of Neuroimmune Metabolism: The Kynurenine Pathway as a Link Between Cognitive and Psychiatric Dysfunction

In this narrative review we summarise some of the roles played by glutamate and its receptors in both epilepsy and schizophrenia, before presenting the kynurenine pathway of tryptophan metabolism as a generator of compounds acting at least partly by modulating those receptors. Increasing evidence indicates that epileps...

Trevor W. Stone, F. Clanchy, Richard O. Williams · 0 citations
Review 2026

Astroglial dysregulation and gliotransmitter imbalance in schizophrenia.

Insight into the scientific concepts that interrelate the pathophysiology of schizophrenia with astroglia dysregulation at the level of gliotransmitter imbalance could provide innovative hints for developing therapeutic strategies for the treatment of schizophrenia.

Mercy Priyadharshini Babu Deva Irakkam, Mahesh Kandasamy · 0 citations
Open access Sep 2026

668. Serotonin, melatonin, and kynurenines: bridging neurochemical pathways in schizophrenia and beyond

Abstract Background Cognitive deficits and metabolic syndrome are highly prevalent in schizophrenia (SCZ), suggesting shared underlying biological mechanisms. Emerging evidence points to the dysregulation of tryptophan (Trp) metabolism, specifically the balance between the serotonin/melatonin (MLT) and kynurenine (Kyn)...

B. Barzon, A. Shkodra, S. Nasini et al. · 0 citations
Open access Sep 2026

243. Dysconnectivity in schizophrenia: evidence at the molecular level via a network analysis of postmortem tissues

Abstract Background Schizophrenia pathophysiology has consistently been associated with disruptions in the glutamatergic pathway, postsynaptic density (PSD) proteins, and monoaminergic neurotransmission, especially the dopaminergic one. Proper functionality of each neurotransmitter system is crucial for brain health, b...

G. De Simone, T. Nuzzo, A. di Maio et al. · 0 citations
Open access Sep 2026

553. Dual Lipopolysaccharide injection induces prolonged activation of the kynurenine pathway and alters schizophrenia-associated proteins in vivo

Abstract Background Schizophrenia is a severe chronic psychiatric disease that affects approximately 0.3% of the population and imposes a substantial emotional and economic burden on families and society worldwide1,2. It is characterized by positive, negative and cognitive symptoms1. Current treatments address the posi...

C. H. Horst, A. Bidar, Å. Wiman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.